Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 13/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL28842421 | 0.93 | BCHE (0.56) | BCHEL3MBTL1KDM4EHTR1AADRA1D | |
| SCHEMBL1952684 | 0.88 | HTR1A (0.63) | L3MBTL1KDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL29859200 | 0.88 | BCHE (0.53) | BCHEL3MBTL1KDM4EHTR1AADRA1D | |
| SCHEMBL21300617 | 0.88 | BCHE (0.67) | BCHEL3MBTL1KDM4EHTR1AADRA1D | |
| SCHEMBL30445162 | 0.87 | HTR1A (0.58) | BCHEL3MBTL1HTR1AADRA1DADRA1A | |
| SCHEMBL11019947 | 0.87 | HTR1A (0.58) | BCHEL3MBTL1HTR1AADRA1DADRA1A | |
| SCHEMBL18623128 | 0.84 | HTR1A (0.68) | BCHEL3MBTL1KDM4EHTR1AADRA1D | |
| SCHEMBL27488692 | 0.84 | HTR1A (0.61) | L3MBTL1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL29000550 | 0.81 | HTR1A (0.57) | BCHEL3MBTL1HTR1AADRA1DADRA1A | |
| SCHEMBL12843212 | 0.81 | BCHE (0.60) | BCHEL3MBTL1KDM4EHTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104860908-B | Method for synthesizing BNC105 | 广东颐正达医药科技有限公司 | 2017-03-22 | — | — | CN | claimed |
| CN-104860908-A | Method for synthesizing BNC105 | GUANGDONG YIZHENGDA PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-08-26 | — | — | CN | claimed |
| CN-116848110-A | Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-107922396-B | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | 建新公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-104860908-B | Method for synthesizing BNC105 | 广东颐正达医药科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-104860908-A | Method for synthesizing BNC105 | GUANGDONG YIZHENGDA PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-08-26 | — | — | CN | disclosed |
| US-8557982-B2 | Tubulin polymerisation inhibitors | BIONOMICS LIMITED (AU) | 2013-10-15 | — | — | US | disclosed |
| US-20120309768-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | BIONOMICS LIMITED (AU) | 2012-12-06 | — | — | US | disclosed |
| US-8278290-B2 | Tubulin polymerisation inhibitors | Biononics Limited (AU) | 2012-10-02 | — | — | US | disclosed |
| US-20100292190-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | BIONOMICS LIMITED (AU) | 2010-11-18 | — | — | US | disclosed |
| EP-1848704-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | Bionomics Limited (AU) | 2007-10-31 | — | — | EP | disclosed |
| EP-0928791-A1 | PROCESS FOR PRODUCING 1,4-BENZODIOXANE DERIVATIVES | DAISO CO., LTD. (JP) | 1999-07-14 | — | — | EP | disclosed |
| US-5780650-A | Process for preparation of 1,4-benzodioxane derivative | DAISO CO., LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0841334-A1 | PROCESS FOR PRODUCING 1,4-BENZODIOXANE DERIVATIVES | DAISO CO., LTD. (JP) | 1998-05-13 | — | — | EP | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0525888-A1 | New catechol type non-steroidal drugs as 5-alpha reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292190-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | TUBB1, TUBA1C, TUBB | BCHE 3606/4885L3MBTL1 3961/4885KDM4E 3805/4885 |
| US-20120309768-A1 | NOVEL TUBULIN POLYMERISATION INHIBITORS | TUBB1, TUBA1C, TUBB | BCHE 3606/4885L3MBTL1 3961/4885KDM4E 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.